COVID-19 Adaptations in the Care of Patients with Opioid Use Disorder: a Survey of California Primary Care Clinics

被引:0
作者
Lauren Caton
Hannah Cheng
Hélène Chokron Garneau
Tammy Fisher
Briana Harris-Mills
Brian Hurley
Sandra Newman
Mark P. McGovern
机构
[1] Stanford University School of Medicine,Center for Behavioral Health Services and Implementation Research, Division of Public Mental Health and Population Sciences, Department of Psychiatry & Behavioral Sciences
[2] Center for Care Innovations,Department of Family Medicine
[3] University of California Los Angeles,Division of Primary Care and Population Health, Department of Medicine
[4] Los Angeles County Department of Health Services,undefined
[5] Stanford University School of Medicine,undefined
来源
Journal of General Internal Medicine | 2021年 / 36卷
关键词
COVID-19; opioid use disorder (OUD); medications for opioid use disorder (MOUD); telehealth; office-based opioid treatment (OBOT);
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:998 / 1005
页数:7
相关论文
共 57 条
[1]  
Volkow ND(2014)Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic New England Journal of Medicine. 370 2063-2066
[2]  
Frieden TR(2019)Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis? Substance Abuse. 40 148-153
[3]  
Hyde PS(2017)Why aren’t physicians prescribing more buprenorphine? Journal of Substance Abuse Treatment. 78 1-7
[4]  
Cha SS(2014)Barriers to primary care physicians prescribing buprenorphine Annals of Family Medicine. 12 128-133
[5]  
Doernberg M(2018)Methadone in primary care - one small step for congress, one giant leap for addiction treatment New England Journal of Medicine. 379 7-8
[6]  
Krawczyk N(2018)Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment American Journal of Preventive Medicine. 54 S230-S242
[7]  
Agus D(2019)Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder: X the X Waiver JAMA Psychiatry. 76 229-230
[8]  
Fingerhood M(2019)Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States International Journal of Drug Policy. 73 42-48
[9]  
Huhn AS(2020)Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic Harm reduction journal. 17 26-26
[10]  
Dunn KE(2020)Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder Am J Psychiatry 177 117-124